Genocea Biosciences Inc. (NASDAQ:GNCA)’s share price fell 4% during trading on Wednesday . The company traded as low as $4.69 and last traded at $4.75, with a volume of 83,598 shares. The stock had previously closed at $4.95.

A number of brokerages recently commented on GNCA. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research note on Monday. Zacks Investment Research downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $17.95.

The firm’s 50 day moving average price is $4.26 and its 200 day moving average price is $4.31. The company’s market cap is $131.47 million.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.05. On average, equities research analysts predict that Genocea Biosciences Inc. will post ($1.63) EPS for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.